Bionest Oncology Capabilities 2016

Bionest Oncology Capabilities
2016
1
Significant Transformation in the Oncology Market
COMBINATION STRATEGY
ADVOCACY STRATEGY
LONGITUDINAL TESTING
PATIENT CENTRIC STRATEGY
INNOVATIVE TRIAL DESIGN
PAYER PATHWAYS
NEXT-GENERATION TECHNOLOGY
ONCONext
QoL vs. SURVIVAL
INCREASING SEGMENTATION
COMPANION DRUG
IMMUNO-ONCOLOGY
BIG DATA COLLECTION
TUMOR AGNOSTIC STRATEGY
BIOMARKER DRIVEN LCM
COMPANION Dx
GENE & PROTEIN SIGNATURES
Novel technologies and treatment approaches are changing oncology drug
development and commercialization strategies. Companies need to adapt in an
increasingly complex environment.
Bionest Oncology Capabilities
2016 – Slide 2
Bionest is a global consulting firm with an experienced management team
America
Bob Easton
Co-Chairman
New York
Europe
Alain Gilbert
Co-Chairman
Paris
Asia
Olivier Lesueur
Managing Director
New York
Mary Koto
Founder
San Diego
Anne-Sophie
Demange
Manager
Paris
Rachel Laing
Manager
Basel
Additional Strategic partner
in South America
Bionest Oncology Capabilities
2016 – Slide 3
Yasuhiro Komatsu
Senior Advisor
Tokyo
Additional Strategic partner
in China
We Support Innovation Across Key Development and Commercialization
Challenges in Oncology
Build a High-Value
Portfolio
Where to play?

Breakthrough technology or
tumor area strategy
 Corporate development
Optimize Brand
Development Strategy
Where are the opportunities?
 In-depth disease landscape
 Opportunity mapping, initial
segmentation and TPP testing
strategy
 Search and scout
How to place the bets?
 Portfolio strategy
 Valuation and risk analysis
 Asset / company due diligence
What is needed to win?
 Customer Journey and key
intervention points

Innovative competitive
differentiation strategies
Prepare for
Commercial Success
How to differentiate?
 Competitive Simulations
 Qual. / Quant. Positioning
 Brand strategic planning
 Customer services / Advocacy
How to maximize value?
 Life cycle strategy
How to Commercialize?
What development strategy?

Value of innovative strategies
– e.g., combination, biomarker
strategies
Bionest Oncology Capabilities
2016 – Slide 4
 Innovative commercial models
 EU / WW market entry
 Drug / Dx commercialization
COMMERCIAL
SUCCESS
BRAND
DEVELOPMENT
PORTFOLIO
Bionest Has Helped its Clients Tackle Key Oncology Business Questions
What external
opportunities should
we consider for our
Hem-Onc portfolio?
 Strategic review of the hem-onc landscape
 Identified and prioritized acquisition targets
 Trade-off analysis, watch list, and recommendations
for the BD team
What immunotherapy
combination strategy
for our targeted
oncology portfolio?
 Assessment of potential immunotherapy partners
 Mapping of opportunity areas where combination(s)
would drive value
 Recommendation on partner and deal strategy
Which oncology
indication(s) should
we prioritize for our
asset?
 Full market assessment of indications in question
 TPP testing and evaluation of potential opportunity
 Assessment of strategic options and scenario planning
to prepare for upcoming decision making
What is the
opportunity for our
novel TKI in gastric
cancer?
 Gastric cancer market review: US, EU, and Japan
 TPP testing and discussion around efficacy thresholds
 Opportunity segments and recommendation on
gastric cancer development strategy
What LCM strategy for
my asset in NSCLC?
 Comprehensive assessment of NSCLC landscape
 Recommendation on priority opportunities to consider
 Key guidelines for commercialization, including
biomarker / CDx strategy
What positioning
strategy for our breast
cancer asset?
 Deep qualitative analysis of breast cancer landscape
 Positioning workshop/competitive simulation
 Quantitative testing of share preference/source of
business by scenario and recommendation
Bionest Oncology Capabilities
2016 – Slide 5
Bionest has a Strong Track Record in Oncology
Extensive Thought Leadership
Selected Articles and Presentations
“Immunotherapy: Big Pharma’s Seductive Embrace”
IN VIVO, Dec. 2014
“Companies are…setting up combination trials early in
clinical development…This notion of seeking synergy from
the get-go is a dramatic shift in how cancer drugs are
developed, with strong implications for partnering, pricing,
and life cycle management”
SEPTEMBER 2015
2016
2016
“Immuno-Oncology Brings New
Opportunities for Developers of
Targeted Cytotoxics”
“Time to be Savvy for
Next-Generation
Immuno-oncology”
“Can CDx Save the NextGeneration of ImmunoOncology?”
Personalized Medicine in Oncology
Article in Progress
Article in Progress
Opdivo and Keytruda have been
approved and incorporated into
standard-of-care in several
indications, with other
approvals on the horizon.
Companies are capitalizing on
immuno-oncology’s (IO)
success, pushing forward with
additional PD-1/L1 inhibitors as
well as next-generation
therapies. These companies face
a highly competitive and
complex market, where past
strategies may prove obsolete
and more savvy bets may drive
success.
First-generation IO agents
have, for the most part, been
widely approved. After the
focus on precision medicine for
molecular therapies, it has
failed to make its way into IO
thus far. However, the IO space
is poised to become increasingly
complex. Experts recognize
that biomarker approaches will
become increasingly important,
but how this will play out and
who will drive this remains to
be seen.
To read these articles and more, visit http://bionest.com/publications/publications/
Bionest Oncology Capabilities
2016 – Slide 6
We Support Decision Making for the Following Clients
Selected Clients
Bionest Oncology Capabilities
2016 – Slide 7
380 Lexington Ave, 43rd Floor
New York, NY 10168
USA
Tel: +1 612 212 3030
19, rue du Général Foy
75008 Paris
France
Tel: +33 1 58 05 14 00
[email protected]
www.bionest.com
Bionest Oncology Capabilities
2016 – Slide 8
8
8